Nuvalent (NUVL) Cash from Investing Activities (2021 - 2026)
Nuvalent (NUVL) reported Cash from Investing Activities of -$19.4 million for Q1 2026, down 176.38% on a YoY basis from $25.4 million in Q1 2025, and up 93.09% quarter-over-quarter from -$280.9 million in Q4 2025.
Nuvalent (NUVL) Cash from Investing Activities (2021 - 2026) Analysis & Trends
Nuvalent has reported Cash from Investing Activities for 6 years, with the latest figure at -$19.4 million in Q1 2026.
- For the quarter ending Q1 2026, Cash from Investing Activities fell 176.38% year-over-year to -$19.4 million; the trailing twelve-month figure through Mar 2026 stood at -$168.9 million (up 50.51% YoY), and the FY2025 full-year result was -$124.1 million, up 78.37% from the prior year.
- Cash from Investing Activities for Q1 2026 stood at -$19.4 million, up from -$280.9 million in the prior quarter.
- The five-year high for Cash from Investing Activities was $77.5 million in Q2 2025, with the low at -$280.9 million in Q4 2025.
- Historically, Cash from Investing Activities has averaged -$51.2 million across 5 years, with a median of $1.6 million in 2023.
- Annual changes were most pronounced in 2023 — Cash from Investing Activities sank 1074.65% — and 2024, when it soared 916.81%.
- Nuvalent's Cash from Investing Activities stood at -$65.4 million in 2022, then gained by 13.98% to -$56.3 million in 2023, then slumped by 202.24% to -$170.0 million in 2024, then plunged by 65.22% to -$280.9 million in 2025, then jumped by 93.09% to -$19.4 million in 2026.
- The last three Cash from Investing Activities figures came in at -$19.4 million (Q1 2026), -$280.9 million (Q4 2025), and $54.0 million (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Investing (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 762,369.55 Bn | 762,369.51 Bn | - | - |
| 2 | Belite Bio | 55,096.00 Bn | 55,096.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,755.80 Bn | 17,755.79 Bn | - | -2.89 Mn |
| 4 | Legend Biotech | 3,486.00 Bn | 3,485.71 Bn | 242.10 Mn | 638.50 Mn |
| 5 | Akari Therapeutics | 1,737.42 Bn | 1,737.41 Bn | - | - |
| 6 | Evaxion A | 1,551.28 Bn | 1,551.26 Bn | - | - |
| 7 | Psyence Biomedical | 227.32 Bn | 227.31 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 110.84 Bn | 103.59 Bn | 2.59 Bn | -431.90 Mn |
| 9 | Abivax | 91.71 Bn | 91.71 Bn | - | 579,519.10 |
| 10 | Nuvalent | 9.70 Bn | 9.70 Bn | - | -19.41 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -19.41 Mn |
| Mar 31, 2026 | -19.41 Mn |
| Dec 31, 2025 | -280.94 Mn |
| Dec 31, 2025 | -280.94 Mn |
| Sep 30, 2025 | 53.97 Mn |
| Sep 30, 2025 | 53.97 Mn |
| Jun 30, 2025 | 77.48 Mn |
| Jun 30, 2025 | 77.48 Mn |
| Mar 31, 2025 | 25.42 Mn |
| Mar 31, 2025 | 25.42 Mn |
| Dec 31, 2024 | -170.05 Mn |
| Dec 31, 2024 | -170.05 Mn |
| Sep 30, 2024 | -212.91 Mn |
| Sep 30, 2024 | -212.91 Mn |
| Jun 30, 2024 | 16.21 Mn |
| Jun 30, 2024 | 16.21 Mn |
| Mar 31, 2024 | -206.77 Mn |
| Mar 31, 2024 | -206.77 Mn |
| Dec 31, 2023 | -56.26 Mn |
| Dec 31, 2023 | -56.26 Mn |